Evidence map›Paper›PMID 28067880›Full record

Trial reportBone marrow transplantation2017

A phase I/II trial of intrabone marrow cord blood transplantation and comparison of the hematological recovery with the Japanese nationwide database.

N Kurita, M Gosho, Y Yokoyama, T Kato, N Obara, M Sakata-Yanagimoto, Y Hasegawa, N Uchida, S Takahashi, Y Kouzai and 4 more

Open access · bronzeAbstract readClinical Trial, Phase IClinical Trial, Phase II
PubMed Publisher
In one paragraph

Trial report in Bone marrow transplantation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Going home for the holidays? Take a shortcut!Bone marrow transplantation · 2017
    Article
  9. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 1 country.

N KuritaDepartment of Hematology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
M GoshoDepartment of Clinical Trial and Clinical Epidemiology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
Y YokoyamaDepartment of Hematology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
T KatoDepartment of Hematology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
N ObaraDepartment of Hematology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
M Sakata-YanagimotoDepartment of Hematology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
Y HasegawaDepartment of Hematology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
N UchidaDepartment of Hematology, Federation of National Public Service Personnel Mutual Aid Associations Toranomon Hospital, Tokyo, Japan.
S TakahashiDivision of Molecular Therapy, The Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Y KouzaiDepartment of Transfusion Medicine, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan.
Y AtsutaJapanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan.
M KurataJapanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan.
T IchinoheDepartment of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
S ChibaDepartment of Hematology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
University of Tsukuba · JPThe Japanese Data Center for Hematopoietic Cell Transplantation · JPHiroshima University · JPThe University of Tokyo · JPTokyo Metropolitan Tama Medical Center · JPToranomon Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intrabone marrow cord blood transplantation (IB-CBT) was proposed as a promising treatment modality to improve hematological recovery. However, clinical advantages of IB-CBT over conventional IV CBT have been unclear. We conducted a prospective single-center trial of IB-CBT to evaluate its safety and superiority in terms of hematological recovery. Fifteen adults with hematological malignancies were enrolled. A thawed and unwashed single cord blood unit was injected into the bilateral superior-posterior iliac crests under local anesthesia. Engraftments of neutrophils and platelets were achieved in 13 cases, with medians of 17 and 45 days, respectively. For the control, we extracted data from the Japanese nationwide database and compared the hematological recovery of contemporaneously transplanted 1135 CBT cases. Multivariate analysis revealed that IB-CBT enhanced platelet recovery (hazard ratio, 2.13; P=0.007), but neutrophil recovery did not differ significantly (hazard ratio, 1.70; P=0.19). Better donor chimerism was seen in the bone marrow of the ilium than of the sternum on day 14, suggesting that the local hematopoiesis at the injected site was established earlier than that at the remote bone marrow site. Collectively, IB-CBT was well tolerated and may enhance local engraftment, which promotes prompter platelet recovery than does IV-CBT.

Indexed as

Graft SurvivalInfusions, IntraosseousAdultAgedBlood PlateletsCord Blood Stem Cell TransplantationFemaleHematologic NeoplasmsHumansIliumInfusions, IntravenousJapanMaleMiddle AgedNeutrophilsSternum

Identifiers

PMID28067880
OpenAlexW2571188233

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.